Characteristics of the 22 patients with CHF
. | No. (%) or median (range) . |
---|---|
Age, y (range) | 70 (49-83) |
Male/female | 12/10 |
Diagnosis | |
CML | 11 (50) |
CML AP | 4 (18) |
MPD | 4 (18) |
CML BP | 2 (9) |
ALL | 1 (5) |
Medical history | |
Hypertension | 10 |
CAD | 8 (36) |
CHF | 6 (27) |
DM | 6 (27) |
Arrythmia | 3 (14) |
Cardiomyopathy | 1 (5) |
Prior IFN-α | 12 (55) |
Prior anthracyclin | 3 (13) |
Decreased LVEF | 9 (41) |
Dose at the time of CHF | |
300 mg | 1 (5) |
400 mg | 8 (36) |
600 mg | 8 (36) |
800 mg | 5 (23) |
Albumin, g/L | 33 (17-49) |
. | No. (%) or median (range) . |
---|---|
Age, y (range) | 70 (49-83) |
Male/female | 12/10 |
Diagnosis | |
CML | 11 (50) |
CML AP | 4 (18) |
MPD | 4 (18) |
CML BP | 2 (9) |
ALL | 1 (5) |
Medical history | |
Hypertension | 10 |
CAD | 8 (36) |
CHF | 6 (27) |
DM | 6 (27) |
Arrythmia | 3 (14) |
Cardiomyopathy | 1 (5) |
Prior IFN-α | 12 (55) |
Prior anthracyclin | 3 (13) |
Decreased LVEF | 9 (41) |
Dose at the time of CHF | |
300 mg | 1 (5) |
400 mg | 8 (36) |
600 mg | 8 (36) |
800 mg | 5 (23) |
Albumin, g/L | 33 (17-49) |
CML AP indicates CML–accelerated phase; CML BP, CML–blastic phase; MPD, myeloproliferative disorders; and CAD, coronary artery disease.